New Reagents for RNA-based Therapeutic Technologies

描述：基于RNA的治疗技术的新试剂摘要功能性RNA分子，如适体、siRNAs、miRNAs和相关化合物，作为人类治疗和阐明体内基因调控的工具具有巨大的潜力。要达到这种潜力，这种分子必须是高度有效和高度稳定的。未经修改的RNA通常不能满足这些要求。通过单独或联合使用2‘-O-甲基-核糖(2’-OME)和硫代磷酸(PS)主链修饰，在体外和体内都取得了一些成功。然而，2‘-OME和PS修饰的RNA在体内的稳定性和活性都有限，这可能是有问题的。此外，含有PS修饰的核糖核酸(S)在磷原子上是手性的，导致在每个PS取代处有两个不同的异构体。因此，有必要进一步改进。在这个项目的第一阶段，我们展示了一种新方法的原理证明，该方法使用含有2‘-OMe-二硫代磷酸酯(MS2)修饰的RNA，该RNA是通过使用新的2’-OMe-硫代亚胺(2‘-OMe-硫代酰胺)试剂制备的。我们成功地小规模合成了四个2‘-OM型硫代酰胺(A、C、G和U)，并用它们合成了各种含有MS2修饰的RNA。值得注意的是，我们发现，加入MS2修饰显著提高了与目标血管内皮生长因子蛋白的结合亲和力1000倍以上，从2 NM提高到1 PM。此外，我们还发现，含有MS2修饰的siRNAs在培养细胞中对多个基因靶点的基因沉默活性增加。为了实现这些新试剂的高潜力，该项目的第二阶段将集中于以下目标：(1)增加2‘-OMe-硫代酰胺的生产规模；(2)优化用于体外和体内应用的MS2-RNA的固相合成方案；(3)确定MS2-RNA双链的热稳定性和结构；(4)验证选定的VEGFMS2-适配子的细胞结合亲和力和特异性；(5)开发在转移性卵巢癌小鼠模型中提高效力和抗肿瘤效果的配方MS2-siRNAs。该项目的成功完成将展示MS2-siRNAs在体外和体内的价值，并将使AM及其商业合作伙伴能够继续进行2‘-OMe-硫代酰胺试剂的全面商业化，并为实现有效的MS2修饰的基于RNA的疗法做出贡献。

DESCRIPTION: New Reagents for RNA-based Therapeutic Technologies Abstract Functional RNA molecules such as aptamers, siRNAs, miRNAs, and related compounds have enormous potential as human therapeutics and as tools for elucidating gene regulation in vivo. To reach this potential, such molecules must be highly potent and highly stable. Unmodified RNAs typically do not come close to meeting these requirements. Some success has been achieved in vitro and in vivo by using 2'-O- methyl-ribose (2'-OMe) and phosphorothioate (PS) backbone modifications, alone or in combination. However, both 2'-OMe and PS modified RNAs have limited in vivo stability and activity, which can be problematic. In addition, RNA containing PS modification(s) are chiral at phosphorus, resulting in two distinct isomers at each PS substitution. Therefore, there is a need for further improvements. In Phase I of this project, we demonstrated proof of principle for a new approach using RNA containing 2'-OMe-phosphorodithioate (MS2) modifications, prepared by using novel 2'-OMe-thiophosphoramidite (2'- OMe-thioamidite) reagents. We successfully synthesized the four 2'-OMe-thioamidites (A, C, G, and U) at small scale and used them to synthesize a variety of RNAs containing MS2 modifications. Significantly, we showed that incorporating MS2 modifications remarkably improved binding affinity toward the targeted VEGF protein more than 1000-fold, from 2 nM to < 1 pM. In addition, we showed that siRNAs containing MS2 modifications had increased gene silencing activity against multiple gene targets in cultured cells. To realize the high potential o these new reagents, Phase II of this project will focus on the following aims: (1) increase the scale of 2'-OMe-thioamidite production; (2) optimize protocols for solid-phase synthesis of MS2-RNA for in vitro and in vivo applications; (3) determine the thermal stability and structure of MS2-RNA duplexes; (4) validate the cellular binding affinity and specificity of the selected VEGF MS2-aptamers; (5) develop formulated MS2-siRNAs that provide increased potency and antitumor efficacy in a murine model of metastatic ovarian cancer. Successful completion of this project will demonstrate the value of MS2-siRNAs in vitro and in vivo, and will enable AM and its commercial partners to proceed with full commercialization of the 2'-OMe- thioamidite reagents and contribute toward the realization of effective MS2 modified RNA-based therapeutics.